Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

VINC
VINCERX PHARMA INC
stock OTC

EOD
Oct 1, 2026
0.0150USD0.000%(0.0000)200
Pre-market
0.00USD-100.000%(-0.02)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
04:06PM EST  Vincerx Pharma Announces Offering Of $150M In Common Stock   Benzinga
Jan 14, 2022
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022   Benzinga
06:07AM EST  HC Wainwright & Co. Initiates Coverage On Vincerx Pharma with Buy Rating, Announces Price Target of $25   Benzinga
Dec 23, 2021
06:42AM EST  Cantor Fitzgerald Initiates Coverage On Vincerx Pharma with Overweight Rating, Announces Price Target of $25   Benzinga
Dec 17, 2021
08:07AM EST  Vincerx Pharma Announces First Patient Dosed In Phase 1 Dose-Escalation Study Of VIP152 In Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Richter Syndrome   Benzinga
08:00AM EST  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the first patient has been dosed in the Companys Phase 1 dose-escalation study of VIP152 in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or Richter Syndrome (RS).   GlobeNewswire Inc
Dec 11, 2021
04:53PM EST  Vincerx Pharma Presented Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at ASH 2021; Said VIP152 Has Increased Selectivity and Potency Compared to Other CDK9 Inhibitors in Development, Consistent Across DLBCL and CLL Models of Disease   Benzinga
03:30PM EST  VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease   GlobeNewswire Inc
Dec 7, 2021
08:04AM EST  Vincerx Pharma Receives Orphan Drug Designation From European Commission For VIP152 For Treatment Of Diffuse Large B-Cell Lymphoma   Benzinga
08:00AM EST  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Companys PTEFb/CDK9 inhibitor, for the treatment of diffuse large B-cell lymphoma (DLBCL).   GlobeNewswire Inc
Dec 6, 2021
08:19AM EST  Vincerx Pharma Hosting Key Opinion Leader Webinar On VIP152 Data Presented At American Society Of Hematology Annual Meeting   Benzinga
08:00AM EST  Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data   GlobeNewswire Inc
Nov 12, 2021
08:00AM EST  Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors   GlobeNewswire Inc
Nov 1, 2021
11:47AM EDT  UPDATE: SVB Leerink On Vincerx Outperform Initiation: Firm Believes 'VIP152 & Its Development Program Represent An Optimized Approach More Likely To Yield Favorable Results'; Acknowledges 'Target Risk For CDK9 Given Historical Challenges'   Benzinga
06:32AM EDT  SVB Leerink Initiates Coverage On Vincerx Pharma with Outperform Rating, Announces Price Target of $24   Benzinga
Sep 16, 2021
07:32AM EDT  Vincerx Pharma Reports $50M Private Placement: To Sell ~3.5M Shares At $14.50/Share   Benzinga
07:30AM EDT  Vincerx Pharma Announces $50 Million Private Placement   GlobeNewswire Inc
Sep 13, 2021
10:42AM EDT  Laidlaw & Co. Initiates Coverage On Vincerx Pharma with Buy Rating, Announces Price Target of $30   Benzinga
Sep 7, 2021
08:00AM EDT  Vincerx Pharma, Inc.(Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat Vincerxs management team will participate in a fireside chat at the2021 Wells Fargo Virtual Healthcare Conference, to be heldSeptember 9-10, 2021.   GlobeNewswire Inc
Aug 25, 2021
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2021   Benzinga
06:03AM EDT  B. Riley Securities Initiates Coverage On Vincerx Pharma with Buy Rating, Announces Price Target of $26   Benzinga
Aug 13, 2021
09:13AM EDT  Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $30   Benzinga
Aug 12, 2021
05:02PM EDT  Vincerx Pharma Q2 EPS $(0.12)   Benzinga
04:05PM EDT  First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors   GlobeNewswire Inc
Jul 1, 2021
05:49AM EDT  Vincerx Pharma CEO Ahmed Hamdy Reported Purchase of 7,830 Shares @ Avg Price of $12.77/Share in Form 4 Filing on Wednesday   Benzinga
Jun 28, 2021
08:00AM EDT  Vincerx Pharma Announces Inclusion in Russell 3000 and   GlobeNewswire Inc
Jun 4, 2021
12:40PM EDT  VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting   GlobeNewswire Inc
08:01AM EDT  Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021   Benzinga
08:00AM EDT  VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting   GlobeNewswire Inc
Jun 3, 2021
04:06PM EDT  Vincerx Pharma Announces First Patient Dosed In Phase 1b Study Of VIP152 In MYC-Driven Relapsed Or Refractory Aggressive Lymphomas And Advanced Solid Tumors   Benzinga
04:05PM EDT  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat the first patient has been dosed in the Companys Phase 1b study of VIP152in MYC-driven relapsed or refractory (R/R) aggressive lymphomas and advanced solid tumors.   GlobeNewswire Inc
May 26, 2021
08:00AM EDT  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat Vincerxs Chief Business Officer,Stuart Hwang, PhD, will present a corporate overview at the Jefferies Virtual Healthcare Conference, to be held June 1-4, 2021.   GlobeNewswire Inc
May 17, 2021
08:01AM EDT  Vincerx Pharma Q1 EPS $(0.46)   Benzinga
08:00AM EDT  Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021   GlobeNewswire Inc
May 6, 2021
08:00AM EDT  Vincerx Pharma, Inc. (Nasdaq: VINC) (the Company), today announced the completion of its redemption event with respect to its outstanding public warrants (the Public Warrants).   GlobeNewswire Inc
Apr 20, 2021
08:01AM EDT  Vincerx Pharma Announces FDA Clearance Of IND For Phase 1b Study Of VIP152 In Chronic Lymphocytic Leukemia And Richter Syndrome   Benzinga
08:00AM EDT  Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021   GlobeNewswire Inc
Apr 10, 2021
08:31AM EDT  VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models   GlobeNewswire Inc
Apr 7, 2021
08:00AM EDT  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat it will be hosting a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET.   GlobeNewswire Inc
Apr 5, 2021
08:00AM EDT  Vincerx Pharma Announces Redemption of Public Warrants   GlobeNewswire Inc
Apr 1, 2021
08:03AM EDT  Vincerx Pharma Announces Formation Of Scientific Advisory Board To Advance Clinical Pipeline   Benzinga
08:00AM EDT  Vincerx Pharma Announces Formation of Scientific Advisory Board to   GlobeNewswire Inc
Mar 23, 2021
08:10AM EDT  Vincerx Pharma FY20 Net Loss $10.7M, Cash, Cash Equivalents $2.3M   Benzinga
08:07AM EDT  Vincerx Pharma Q4 EPS $(2.04)   Benzinga
08:00AM EDT  License agreement with Bayer AG secures oncology portfolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity   GlobeNewswire Inc
Mar 19, 2021
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 16, 2021
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
Mar 10, 2021
04:35PM EST  Vincerx Announces Poster At The American Association For Cancer Research 2021; Poster Titled 'A novel small molecule drug conjugate -v3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types'   Benzinga
04:32PM EST  Vincerx Pharma, Inc. (Nasdaq: VINC),a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announceda poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2021, being held virtually April 10-15, 2021.   GlobeNewswire Inc
Mar 2, 2021
08:00AM EST  Vincerx Pharma Strengthens Management Team with Three New Appointments   GlobeNewswire Inc
Feb 24, 2021
08:00AM EST  Vincerx Pharma, Inc. (Nasdaq: VINC),a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat it will be hosting a key opinion leader (KOL) meeting on VIP152 for the treatment of hematologic and solid tumors on Friday, March 5, 2021 at 12:00pm Eastern Time.   GlobeNewswire Inc
Feb 17, 2021
08:00AM EST  Vincerx Pharma to Participate in the 10th Annual SVB Leerink   GlobeNewswire Inc
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Feb 2, 2021
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
Jan 29, 2021
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 7, 2021
04:07PM EST  Vincera Pharma Announces Name Change To Vincerx   RTTNews
Jan 6, 2021
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
04:51AM EST  Chardan Capital Initiates Coverage On Vincera Pharma with Buy Rating, Announces Price Target of $33   Benzinga
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Dec 23, 2020
10:25AM EST  Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC